Novo Nordisk's Rybelsus hasn't lived up to expectations, say analysts
The Danish drugmaker’s diabetes pill hasn’t reached the success that was predicted three years ago, to the disappointment of analysts.
by marketwire, translated by daniel pedersen
Novo Nordisk’s Rybelsus, a diabetes pill, is far from becoming the huge sales success it was heralded as prior to launching a realization that is now disappointing analysts, reports Danish financial media Finans.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
